Groundbreaking AI-Powered Prostate Cancer Treatment Optimization Tool Now Available at Associated Medical Professionals of NY, a U.S. Urology Partners Affiliate in Central New York

Associated Medical Professionals (A.M.P.) announced today the availability of the ArteraAI Prostate Test, an AI-powered risk stratification tool to help personalize and optimize treatments for patients with localized prostate cancer. Dr. Steven E. Finkelstein, National Director of the Center of Advanced Radiation Excellence (CARE) for U.S. Urology Partners and Director Radiation Oncology Research, helped in the development of the tool and was instrumental in its approval process.

“We were excited to be the first in New York to order the ArteraAI Prostate Test for our patients with prostate cancer. Cancer is a scary diagnosis for any patient, but with this new test, we can personalize care and help ensure that the treatments we prescribe will lead to the best outcomes,” said Dr. Steven E. Finkelstein. “The low cost and fast turnaround of the test make it much more accessible for patients while providing physicians with advanced information to identify optimal treatment plans.”

Prostate cancer is the second-leading cause of cancer death in American men, behind only lung cancer. Prostate cancer is a serious disease, but most men diagnosed with prostate cancer do not die from it. More than 3.5 million men in the United States who have been diagnosed with prostate cancer are still alive today, according to the American Cancer Society. Because of the variability in prostate cancer aggressiveness, a major challenge facing clinicians and patients is determining the right treatment options, as both under- and over-treatment can be an issue.

The ArteraAI Prostate Test is the only test in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer. The ArteraAI Prostate Test can increase patients' confidence by offering more clarity around whether they will benefit from a specific treatment course.

Dr. Christopher M. Pieczonka, CEO of Associated Medical Professionals of NY, stated, “The use of multimodal artificial intelligence (MMAI - Artera) is a game changer for New York State patients. This is the only test that has prostate cancer specific mortality as a prognostic endpoint in localized prostate cancer, which enables us to identify the most beneficial treatment plans and provide the highest level of care to our patients.”

Artera’s multimodal artificial intelligence biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular prostate cancer therapy and has been validated using many Phase 3 randomized trials.

About Associated Medical Professionals of NY (A.M.P.)

Associated Medical Professionals of New York (A.M.P.) is a medical practice based in Syracuse serving the Central New York region. Established in 2008, A.M.P. has grown to become one of the largest groups of its kind in the area with nine offices and services at 13 hospitals. As a pivotal point of care in each community, A.M.P. is able to provide continuity of care for a vast population of patients. A.M.P. maintains a robust suite of services, including advanced urological care, robotic surgery, cancer care, radiation oncology, interventional radiology, pathology, lithotripsy, imaging and clinical research. For more information about A.M.P., visit www.ampofny.com.

About U.S. Urology Partners

U.S. Urology Partners offers a comprehensive suite of practice management capabilities to its affiliated community-based urology practices, which maintain their local brand and identity that they have established, often over decades. U.S. Urology Partners currently supports five affiliated groups comprising over 180 providers across practices located in Florida, Indiana, Massachusetts, New York and Ohio. For more information, please visit www.us-uro.com.

About Artera

Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test. Artera’s laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera’s laboratory in Jacksonville, Florida, and can be ordered online at www.artera.ai.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250708856339/en/